Company Name, Ticker, Suppliers, else..

Pmv Pharmaceuticals Inc (NASDAQ: PMVP)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Pmv Pharmaceuticals Inc 's

Name: Pmv Pharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PMVP Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Pmv Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 15.8 %, recorded in the same quarter.

• List of PMVP Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Pmv Pharmaceuticals Inc recorded a net loss, as well as most of its competitors.

<< PMVP Stock Performance Comparisons

<< See the full list of PMVP competitors

*Market share is calculated based on total revenue.

News about Pmv Pharmaceuticals Inc Contracts

Emerging Hope for Cancer Treatment PMV Pharmaceuticals Presents Encouraging Interim Data from PYNNACLE Trial on Rezat...

September 10, 2025
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PRINCETON, N.J., Sept. 10, 2025 PMV Pharmaceuticals, Inc. (PMV Pharma or the Company; Nasdaq: PMVP), a pioneering force in precision oncology, has announced significant interim findings from the pivotal Phase 2 segment of its ongoing PYNNACLE clinical trial. This innovative trial is designed to assess the efficacy of rezatapopt a targeted small molecule therapy specifically in patients diagnosed with advanced solid tumors that express the TP53 Y220C mutation.The TP53 gene is a critical player in tumor suppression, and mutations such as Y220C can dis...

PMVP's Stock Performance relative to its Competitors

Publicly Traded Peers of Pmv Pharmaceuticals Inc

Zymeworks Inc
Share Performance

+12.40%

This Year

Zymeworks Inc

Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,234.867 mill.	$ 81.263 mill.	$ -102.656 mill.

Nextcure Inc
Share Performance

+27.16%

30 Days

Nextcure Inc

Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 38.508 mill.	$ - mill.	$ -54.664 mill.

Nuvectis Pharma inc
Share Performance

+19.00%

30 Days

Nuvectis Pharma inc

Profile

Nuvectis Pharma Inc's business model appears to focus on the development and commercialization of pharmaceutical products.

More about Nuvectis Pharma inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 561.546 mill.	$ - mill.	$ -30.275 mill.

Nuvalent Inc
Share Performance

+18.03%

This Quarter

Nuvalent Inc

Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,751.979 mill.	$ - mill.	$ -450.074 mill.

Nurix Therapeutics Inc
Share Performance

+179.28%

One Year

Nurix Therapeutics Inc

Profile

Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.

More about Nurix Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,829.320 mill.	$ 36.766 mill.	$ -341.351 mill.

47 more competitors available

Sources: Pmv Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 3, 2026 4:20 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pmv Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.